178 related articles for article (PubMed ID: 32841040)
41. Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART.
Okochi H; Louie A; Phung N; Zhang K; Tallerico RM; Kuncze K; Spinelli MA; Koss CA; Benet LZ; Gandhi M
Drug Test Anal; 2021 Jul; 13(7):1354-1370. PubMed ID: 33742745
[TBL] [Abstract][Full Text] [Related]
42. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
Gaur AH; Kizito H; Prasitsueubsai W; Rakhmanina N; Rassool M; Chakraborty R; Batra J; Kosalaraksa P; Luesomboon W; Porter D; Shao Y; Myers M; Ting L; SenGupta D; Quirk E; Rhee MS
Lancet HIV; 2016 Dec; 3(12):e561-e568. PubMed ID: 27765666
[TBL] [Abstract][Full Text] [Related]
43. Emtricitabine seminal plasma and blood plasma population pharmacokinetics in HIV-infected men in the EVARIST ANRS-EP 49 study.
Valade E; Tréluyer JM; Illamola SM; Bouazza N; Foissac F; De Sousa Mendes M; Lui G; Chenevier-Gobeaux C; Suzan-Monti M; Rouzioux C; Assoumou L; Viard JP; Hirt D; Urien S; Ghosn J;
Antimicrob Agents Chemother; 2015 Nov; 59(11):6800-6. PubMed ID: 26282407
[TBL] [Abstract][Full Text] [Related]
44. Oligo(Lactic Acid)
Tam YT; Repp L; Ma ZX; Feltenberger JB; Kwon GS
Pharm Res; 2019 Mar; 36(5):70. PubMed ID: 30888509
[TBL] [Abstract][Full Text] [Related]
45. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes.
Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M
HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199
[TBL] [Abstract][Full Text] [Related]
46. Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys.
Durand-Gasselin L; Van Rompay KK; Vela JE; Henne IN; Lee WA; Rhodes GR; Ray AS
Mol Pharm; 2009; 6(4):1145-51. PubMed ID: 19545170
[TBL] [Abstract][Full Text] [Related]
47. Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Gunawardana M; Dawson LN; Olive TJ; Pyles RB; Baum MM
PLoS One; 2018; 13(8):e0201952. PubMed ID: 30133534
[TBL] [Abstract][Full Text] [Related]
48. Development of lipophilic ester prodrugs of dolutegravir for intestinal lymphatic transport.
Chu Y; Wong A; Chen H; Ji L; Qin C; Feng W; Stocks MJ; Gershkovich P
Eur J Pharm Biopharm; 2023 Oct; 191():90-102. PubMed ID: 37634824
[TBL] [Abstract][Full Text] [Related]
49. Dose finding study for on-demand HIV pre-exposure prophylaxis for insertive sex in sub-Saharan Africa: results from the CHAPS open label randomised controlled trial.
Herrera C; Serwanga J; Else L; Limakatso L; Opoka D; Ssemata AS; Pillay AD; Namubiru P; Seiphetlo TB; Odoch G; Mugaba S; Seatlholo P; Alieu A; Penchala SD; Muhumuza R; Alinde B; Petkov S; O'Hagan K; Callebaut C; Seeley J; Weiss H; Khoo S; Chiodi F; Gray CM; Kaleebu P; Webb EL; Martinson N; Fox J;
EBioMedicine; 2023 Jul; 93():104648. PubMed ID: 37327677
[TBL] [Abstract][Full Text] [Related]
50. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.
Markowitz M; Zolopa A; Squires K; Ruane P; Coakley D; Kearney B; Zhong L; Wulfsohn M; Miller MD; Lee WA
J Antimicrob Chemother; 2014 May; 69(5):1362-9. PubMed ID: 24508897
[TBL] [Abstract][Full Text] [Related]
51. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP;
Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590
[TBL] [Abstract][Full Text] [Related]
52. In vitro photodynamic effects of scavenger receptor targeted-photoactivatable nanoagents on activated macrophages.
Yi BG; Park OK; Jeong MS; Kwon SH; Jung JI; Lee S; Ryoo S; Kim SE; Kim JW; Moon WJ; Park K
Int J Biol Macromol; 2017 Apr; 97():181-189. PubMed ID: 28082222
[TBL] [Abstract][Full Text] [Related]
53. Scavenger receptor A1 attenuates aortic dissection via promoting efferocytosis in macrophages.
Zhang Z; Jiang Y; Zhou Z; Huang J; Chen S; Zhou W; Yang Q; Bai H; Zhang H; Ben J; Zhu X; Li X; Chen Q
Biochem Pharmacol; 2019 Oct; 168():392-403. PubMed ID: 31381873
[TBL] [Abstract][Full Text] [Related]
54. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Sax PE; DeJesus E; Mills A; Zolopa A; Cohen C; Wohl D; Gallant JE; Liu HC; Zhong L; Yale K; White K; Kearney BP; Szwarcberg J; Quirk E; Cheng AK;
Lancet; 2012 Jun; 379(9835):2439-2448. PubMed ID: 22748591
[TBL] [Abstract][Full Text] [Related]
55. Species-specific optimization of PEG~SN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograft.
Fontaine SD; Hann B; Reid R; Ashley GW; Santi DV
Cancer Chemother Pharmacol; 2019 Oct; 84(4):729-738. PubMed ID: 31321449
[TBL] [Abstract][Full Text] [Related]
56. Development and characterization of a long-acting nanoformulated abacavir prodrug.
Singh D; McMillan J; Hilaire J; Gautam N; Palandri D; Alnouti Y; Gendelman HE; Edagwa B
Nanomedicine (Lond); 2016 Aug; 11(15):1913-27. PubMed ID: 27456759
[TBL] [Abstract][Full Text] [Related]
57. Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).
Kulkarni R; Hodder SL; Cao H; Chang S; Miller MD; White KL
HIV Clin Trials; 2017 Jul; 18(4):164-173. PubMed ID: 28891788
[TBL] [Abstract][Full Text] [Related]
58. A Pharmacokinetic/Pharmacodynamic Model to Predict Effective HIV Prophylaxis Dosing Strategies for People Who Inject Drugs.
Garrett KL; Chen J; Maas BM; Cottrell ML; Prince HA; Sykes C; Schauer AP; White N; Dumond JB
J Pharmacol Exp Ther; 2018 Nov; 367(2):245-251. PubMed ID: 30150483
[TBL] [Abstract][Full Text] [Related]
59. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.
Fan J; Fang G; Wang X; Zeng F; Xiang Y; Wu S
Nanotechnology; 2011 Nov; 22(45):455102. PubMed ID: 22019849
[TBL] [Abstract][Full Text] [Related]
60. Synthesis, in vitro and in vivo release kinetics, and anti-HIV activity of a sustained-release prodrug (mPEG-AZT) of 3'-azido-3'-deoxythymidine (AZT, Zidovudine).
Li W; Chang Y; Zhan P; Zhang N; Liu X; Pannecouque C; De Clercq E
ChemMedChem; 2010 Nov; 5(11):1893-8. PubMed ID: 20936623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
